Top Page
DRI Healthcare
(TSX:DHT.UN)
DRI Healthcare (DHT.UN) vs. iShares MSCI Canada ETF (EWC)
DRI Healthcare Business Overview & Revenue Model
DRI Healthcare Earnings Call Summary
DRI Healthcare Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 160.88M | 138.55M | 117.44M | 79.87M | 73.33M | 0.00 |
| Gross Profit | 133.30M | 66.60M | -20.36M | 79.87M | 73.33M | 0.00 |
| EBITDA | 65.45M | -4.94M | 105.68M | 76.77M | 66.06M | 0.00 |
| Net Income | 3.93M | -3.36M | 91.50M | 11.60M | 21.56M | -2.17K |
Balance Sheet | ||||||
| Total Assets | 967.26M | 984.87M | 833.16M | 633.42M | 436.69M | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 82.50M | 36.50M | 62.84M | 36.69M | 61.71M | 0.00 |
| Total Debt | 447.23M | 432.12M | 145.48M | 244.99M | 43.92M | 0.00 |
| Total Liabilities | 463.66M | 457.34M | 273.46M | 261.08M | 57.71M | 362.00 |
| Stockholders Equity | 503.60M | 527.53M | 561.50M | 372.34M | 378.99M | -352.00 |
Cash Flow | ||||||
| Free Cash Flow | -20.84M | -129.84M | -313.90M | -197.03M | -232.46M | 0.00 |
| Operating Cash Flow | 146.16M | 155.41M | 76.38M | 77.47M | 91.86M | 0.00 |
| Investing Cash Flow | -169.09M | -293.31M | -128.81M | -273.67M | -372.33M | 0.00 |
| Financing Cash Flow | 51.67M | 111.56M | 78.57M | 171.17M | 342.18M | 60.00 |
DRI Healthcare Technical Analysis
DRI Healthcare Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $378.88M | 22.60 | 12.25% | ― | 121.40% | -47.34% | |
| ― | C$836.19M | 155.07 | 0.78% | 3.81% | 0.03% | -56.81% | |
| ― | C$87.10M | 65.69 | 1.88% | ― | 0.03% | -17.30% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$175.14M | ― | -20.58% | ― | -1.42% | 35.15% | |
| ― | $581.12M | 1,714.71 | 0.03% | ― | 13.82% | ― | |
| ― | C$11.38M | ― | -7.15% | ― | 10.84% | 48.57% |
DRI Healthcare Corporate Events
DRI Healthcare Trust has announced the acquisition of a synthetic royalty interest in the U.S. sales of veligrotug and VRDN-003, treatments for Thyroid Eye Disease (TED), from Viridian Therapeutics. This transaction, valued at up to $300 million, is DRI’s third synthetic royalty transaction and further increases its portfolio exposure to rare diseases. Veligrotug has shown promising clinical results and has been granted Breakthrough Therapy Designation by the FDA, potentially accelerating its regulatory review. If approved, it will be the second biologic treatment for TED, offering improved patient outcomes with fewer doses. The deal is expected to enhance DRI’s long-term cash flows and strengthen its position in the rare disease market.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Hold with a C$15.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
DRI Healthcare Trust has announced it will host a conference call on November 6, 2025, to discuss its third quarter financial results, which will be released the day before. This event provides an opportunity for stakeholders to engage with the company’s management and gain insights into its financial performance and strategic direction.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Hold with a C$15.50 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
DRI Healthcare Trust has promoted Zaheed Mawani to the position of Chief Financial Officer, effective October 1, 2025. Mr. Mawani, who joined the company as Chief Compliance Officer in 2024, brings over 30 years of financial leadership experience from major public companies. This strategic move underscores DRI Healthcare’s commitment to leveraging internal talent for its growth. The outgoing CFO, Amit Kapur, will assist in a smooth transition until the end of September.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
DRI Healthcare Trust announced its participation in upcoming investor conferences, including the 24th Annual CIBC Eastern Institutional Investor Conference in Montreal and the Raymond James Dividend & Royalty Conference in Toronto. These presentations are significant for DRI Healthcare as they provide an opportunity to engage with investors and showcase their strategic initiatives, potentially impacting their market positioning and stakeholder relations.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
DRI Healthcare has reported its second quarter 2025 financial results, highlighting a significant transformation with the internalization of its investment management function, which aligns management and unitholder interests. The company achieved a total income of $44.1 million and completed a notable transaction to enhance its royalty entitlement, positioning itself for sustainable future returns.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
DRI Healthcare Trust announced it will host a conference call and webcast to discuss its second quarter 2025 financial results on August 14, 2025. The company will release its financial results on August 13, 2025, after market close. This announcement is significant as it provides stakeholders with an opportunity to gain insights into the company’s financial performance and strategic direction, potentially impacting investor confidence and market positioning.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.